FIE Fielmann Group AG
Fielmann Group AG engages in vision care and audiology business in Germany, Switzerland, Austria, Spain, North America, and internationally. The company manufactures and sells visual aids mainly glasses, eyewear frames and lenses, sunglasses, contact lenses, ready-made reading glasses, hearing systems and its accessories, as well as personal protective equipment. It also offers its products under the fielmann, Optika Clarus, Optica & Audiologia Universitaria, Medical optica audicion, Shopko Optical, and SVS VISION brand names. The company sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform. The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is headquartered in Hamburg, Germany. Fielmann Group AG operates as a subsidiary of Korva SE.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Fielmann Group (ETR: FIE)
›
Fielmann Group (ETR: FIE) is listed on Xetra (Frankfurt), where its shares trade in EUR. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 18,213 employees.
The shares were at 42.30 EUR on 19 November 2026, down 2.4% over 52 weeks. Its 52-week range is 36.65 EUR to 47.95 EUR: the price is 11.8% below the high and 15.4% above the low.
At a market capitalisation of 3.55B EUR, it trades at 16.1 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 67% for FIE. It pays a dividend yielding 3.25% (it pays out 55% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Fielmann Group reports return on equity of 20.8%, an operating margin of 13.7% and revenue up 4.7% year over year.
Its debt exceeds its cash by 625.16M EUR, a debt-to-equity ratio of 0.90. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 54.88 EUR is 29.7% above the current price. The next earnings report is expected on 3 March 2027.